logo

For the Inventor, By the Inventor

Novato, CA, United States of America

Ultragenyx Pharmaceutical Inc.

Calculating rank
USPTO Granted Patents = 36

% Expired Patents = 2.8



Trademarks = 11

Forward Citations = 43

Loading Chart...
Loading Chart...

45 inventors (with patents filed for the assignee):

goldMedal Emil D Kakkis (20 out of 47 patents)

silverMedal Steven Jungles (12 out of 15 patents)

bronzeMedal Gabrielle Morris (7 out of 7 patents)

4.  He Zhao (5 out of 34 patents)

5.  Sean Christopher Daugherty (5 out of 6 patents)

6.  Javier San Martin (4 out of 4 patents)

7.  Tomohiro Sudo (4 out of 4 patents)

8.  Michael Vellard (4 out of 4 patents)

9.  Jeff Grubb (4 out of 4 patents)

10.  Samuel C Wadsworth (4 out of 27 patents)

11.  Sharyl Fyffe-Maricich (3 out of 3 patents)

12.  John Klopp (3 out of 4 patents)

13.  Kelly Reed Clark (3 out of 10 patents)

14.  Stewart Craig (3 out of 3 patents)

15.  Matthew Scott Fuller (3 out of 3 patents)


Core Competencies:
Glycogen Storage Disease
Gene Therapy
Propionic Acidemia
Sialic Acid Deficiencies
Recombinant AAV
Transfection Reagents
HDAC Inhibitors
Creatine Prodrugs
Sialylated Glycoproteins
Tumor-Induced Osteomalacia
Phosphorous Concentration
Adenovirus Inactivation

36 patents:

1. 12766124 - Compositions of triglycerides and uses thereof (2026-10-20),
2. 12766123 - Compositions of triglycerides and uses thereof (2026-10-20),
3. 12703858 - THERAPEUTICS FOR GLYCOGEN STORAGE DISEASE TYPE III (2026-08-11),
4. 12692512 - METHODS AND COMPOSITIONS FOR TREATING GLYCOGEN STORAGE DISEASES (2026-07-28),
5. 12686874 - GENE THERAPY FOR TREATING PROPIONIC ACIDEMIA (2026-07-21),
6. 12649006 - GENE THERAPY FOR TREATING CDKL5 DEFICIENCY DISORDER (2026-06-09),
7. 12551461 - Compositions of triglycerides and uses thereof (2026-02-17),
8. 12544437 - METHODS FOR IMPROVED THERAPEUTIC USE OF RECOMBINANT AAV (2026-02-10),
9. 12487152 - Scalable method for producing transfection reagents (2025-12-02),
10. 12472268 - GENE THERAPY FOR TREATING PROPIONIC ACIDEMIA (2025-11-18),
11. 12358976 - Methods for increasing serum concentration of phosphorous and/or 1,25-hydroxy vitamin d (2025-07-15),
12. 12338450 - Gene therapy constructs for treating Wilson disease (2025-06-24),
13. 12018288 - Engineered producer cell lines and methods of making and using the same (2024-06-25),
14. 11944658 - Methods of heat inactivation of adenovirus (2024-04-02),
15. 11898170 - Cell culture methods involving HDAC inhibitors or rep proteins (2024-02-13),
Company Overview
Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company focused on the development of innovative therapies for rare and ultra-rare genetic diseases. The company specializes in the research and commercialization of novel treatments that address significant unmet medical needs. With a commitment to advancing science and improving patient outcomes, Ultragenyx operates primarily in the biotechnology sector, leveraging cutting-edge technology and research methodologies to bring transformative therapies to market.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 27 2026

36 Patents

#4 in Novato, CA

#2,252 in California

#9,521 in US

#18,756 in the World

Novato, CA (US)
Novato, CA, United States of America

Ultragenyx Pharmaceutical Inc.

Forward Citations = 43

45 inventors:

goldMedal Emil D Kakkis (20 out of 47 patents)

silverMedal Steven Jungles (12 out of 15 patents)

bronzeMedal Gabrielle Morris (7 out of 7 patents)

4.  He Zhao (5 out of 34 patents)

5.  Sean Christopher Daugherty (5 out of 6 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Ultragenyx Pharmaceutical Inc.. Retrieved from https://idiyas.com/company/ultragenyx-pharmaceutical

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…